Everything below concerns somatotroph. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
==== United States ==== Mephedrone has been implicated in the death of a 22-year-old man, who had also injected black tar heroin. Mephedrone was found in his blood at a concentration of 0.50 mg/L and in his urine at a concentration of 198 mg/L. The blood concentration of morphine, a metabolite of heroin, was 0.06 mg/L. For comparison, the average blood morphine concentration resulting from deadly overdoses involving only heroin is around 0.34 mg/L.
Archives of Biochemistry and Biophysics is a biweekly peer-reviewed scientific journal that covers research in biochemistry and biophysics. It is published by Elsevier. As of 2012, the editors-in-chief were Paul Fitzpatrick (University of Texas Health Science Center at San Antonio), Helmut Sies (University of Düsseldorf), Jian-Ping Jin (Wayne State University School of Medicine), and Henry Jay Forman (University of Southern California). The journal was established in 1942 by Academic Press as the Archives of Biochemistry, obtaining its current name in 1952. It absorbed the journal Molecular Cell Biology Research Communications (formerly section B of Biochemical and Biophysical Research Communications), which was published from 1999 to 2001. An index to authors for the first 75 volumes, covering the period from 1943 to 1958, was published in October 1959.
The ISOLDE COOLer (ISCOOL) is located downstream from the HRS, and extends up to the merging switchyard joining the two mass separator beams. ISCOOL is a general-purpose Radio Frequency Quadrupole Cooler and Buncher (RFQCB), with the purpose of cooling (improving the beam quality) and bunching the RIB from the HRS. Incoming ions collide with the neutral buffer gas, losing their energy, and then are radially confined. The beam is then extracted from ISCOOL.
A midazolam overdose is considered a medical emergency and generally requires the immediate attention of medical personnel. Benzodiazepine overdose in healthy individuals is rarely life-threatening with proper medical support; however, the toxicity of benzodiazepines increases when they are combined with other CNS depressants such as alcohol, opioids, or tricyclic antidepressants. The toxicity of benzodiazepine overdose and the risk of death are also increased in the elderly and those with obstructive pulmonary disease or when used intravenously. Treatment is supportive; activated charcoal can be used within an hour of the overdose. The antidote for an overdose of midazolam (or any other benzodiazepine) is flumazenil. While effective in reversing the effects of benzodiazepines it is not used in most cases as it may trigger seizures in mixed overdoses and benzodiazepine dependent individuals. Symptoms of midazolam overdose can include:
Sources: en.wikipedia.org
== Economy == Behind Tower Hamlets, Brent has the highest poverty rate in London after housing costs. It was the borough with the highest average unemployment rate in 2022 with 7%. More than one in three households live in poverty, 9% above the London average, and 14% above the England average. Diageo has its head office in Park Royal and in Brent, on a former Guinness brewery property. The brewery was closed in 2004; it had produced beer since 1936. Diageo planned to move its head office to Brent from Central London when the lease on the Central London office expired in 2010.
== Education == Lectka completed his bachelor's in chemistry and graduated from Oberlin College in 1985. He completed his doctoral degree in organic chemistry from Cornell University in 1991. He then completed his postdoctoral studies as an Alexander von Humboldt Postdoctoral Fellow at the University of Heidelberg in Germany and then as a National Institutes of Health Postdoctoral Fellow at Harvard University.
=== Time === Moscow serves as the reference point for the time zone used in most of European Russia, Belarus, and Crimea. These areas operate in Moscow Standard Time (MSK, МСК), which is 3 hours ahead of UTC (or UTC+3). Daylight saving time is no longer observed in Moscow. According to geographical longitude, the average solar noon in Moscow occurs at 12:30.
Other antioxidants are not obtained from the diet, but instead are made in the body. For example, ubiquinol (coenzyme Q) is poorly absorbed from the gut and is made through the mevalonate pathway. Another example is glutathione, which is made from amino acids. As any glutathione in the gut is broken down to free cysteine, glycine and glutamic acid before being absorbed, even large oral intake has little effect on the concentration of glutathione in the body. Although large amounts of sulfur-containing amino acids such as acetylcysteine can increase glutathione, no evidence exists that eating high levels of these glutathione precursors is beneficial for healthy adults.
==== MeSH E05.393.661 – nucleic acid hybridization ==== MeSH E05.393.661.124 – branched dna signal amplification assay MeSH E05.393.661.250 – heteroduplex analysis MeSH E05.393.661.475 – in situ hybridization MeSH E05.393.661.475.350 – in situ hybridization, fluorescence MeSH E05.393.661.475.350.125 – chromosome painting MeSH E05.393.661.475.680 – primed in situ labeling MeSH E05.393.661.640 – oligonucleotide array sequence analysis
Sources: en.wikipedia.org
In pharmacokinetics, steady state refers to the situation where the overall intake of a drug is fairly in dynamic equilibrium with its elimination. In practice, it is generally considered that once regular dosing of a drug is started, steady state is reached after 3 to 5 times its half-life. In steady state and in linear pharmacokinetics, AUCτ=AUC∞.
=== Legal status === In April 2025, the European Medicines Agency (EMA) recommended the refusal of a marketing authorization for Winlevi, a medicine intended for treating acne vulgaris. The EMA noted that Winlevi is a new class of medicine that blocks receptors for androgens. However, there is a risk of the medicine suppressing the working of three organs: the hypothalamus and pituitary glands in the brain and adrenal glands. The suppression of these organs could lead to impaired growth and sexual maturation, which is a major concern in adolescents. Although the company presented data to show that the risk was low, the EMA considered that these data, as well as measures the company proposed to minimize the risk, were not sufficient to approve the medicine for people from 12 years of age to less than 18 years of age. In May 2025, Cassiopea requested a re-examination of the EMA's April 2025 opinion. In October 2025, EMA issued marketing authorization for Winlevi.
==== Absorption ==== The absolute bioavailability of suvorexant is 82% at a dose of 10 mg. Suvorexant exposure does not increase dose-proportionally over a dose range of 10 to 100 mg, which is likely due to decreased absorption at higher doses. Exposure to suvorexant increases by about 75% with a doubling of dose from 20 mg to 40 mg. The time to peak levels of suvorexant is 2 to 3 hours regardless of dose but with wide variation (range 30 minutes to 8 hours). Taking suvorexant with food does not modify suvorexant peak levels or area-under-the-curve levels (overall exposure) but does delay the time to peak concentrations by about 1.5 hours. Steady-state levels of suvorexant with once-daily continuous administration are reached within 3 days. Levels of suvorexant accumulate minimally, by about 1.2- to 1.6-fold, with repeated once-daily administration.
The advantages of supercritical fluid extraction (compared with liquid extraction) are that it is relatively rapid because of the low viscosities and high diffusivities associated with supercritical fluids. Alternative solvents to supercritical fluids may be poisonous, flammable or an environmental hazard to a much larger extent than water or carbon dioxide are. The extraction can be selective to some extent by controlling the density of the medium, and the extracted material is easily recovered by simply depressurizing, allowing the supercritical fluid to return to gas phase and evaporate leaving little or no solvent residues. Carbon dioxide is the most common supercritical solvent. It is used on a large scale for the decaffeination of green coffee beans, the extraction of hops for beer production, and the production of essential oils and pharmaceutical products from plants. A few laboratory test methods include the use of supercritical fluid extraction as an extraction method instead of using traditional solvents.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.